1. Scrip
  2. >>Business
  3. >>Legal & IP

Mylan Clears Runway For US Herceptin Biosimilar Launch

 
• By Jessica Merrill

The generic drug manufacturer is poised to be first to market with a biosimilar version of Roche’s blockbuster breast cancer therapy after reaching a license agreement. The date of a potential launch remains confidential.

airport runway under the sun as background

Mylan NV could be the first manufacturer to launch a biosimilar version of Roche’s blockbuster breast cancer treatment Herceptin (trastuzumab) in the US. The company has an application for a version of trastuzumab pending at FDA with a user fee date of Sept. 3., and now the company has also cleared the crucial intellectual property hurdle.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

Deal Watch: FTC Keeps Current Merger Guidelines In Place, For Now

 
• By Joseph Haas

Plus deals involving Incyte/Genesis, Merck & Co./Epitopea, Merck Serono/Asceneuron, Tivic Health/Statera and more.

India Digital Personal Data Protection Norms: What It May Mean For Clinical Trials, Big Pharma GCCs

 
• By Anju Ghangurde

Legal heavyweights from Nishith Desai Associates, Anand and Anand, Corporate Law Group and EY partner and national cyber leader outline key compliance aspects that pharma and their global capability centers may need to factor as India moves to strengthen the framework for the protection of digital personal data.

Semaglutide In 2027 Medicare Price Negotiations; Most Other Drugs Lose Exclusivity By Then

 
• By Mandy Jackson

Novo took the biggest stock price hit of all the drug makers with products subject to Medicare price negotiations in 2027 under the IRA, but at least 11 of its peers on the list will be subject to generic competition between 2025 and 2027.

Lens On Pharma Marketing ‘Ploys’ In India: Can The Genie Be Tamed?

 
• By Anju Ghangurde

India cracks down on unethical marketing practices, with AbbVie in the eye of a storm for allegedly violating norms. While the action sends the right signal, a wider clean up including in the devices segment, where things may be “more harmful” may not be easy, say some experts.

More from Business

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.